translational research that will meaningfully reduce the burden of ovarian cancer. A critical part of this process is to increase the quality and depth of the translational investigator base in ovarian cancer. The Career Development Program is based on the conviction that translational research can effectively proceed from the bench/population to the clinic or from the clinic to the bench/population. The ultimate objectives of the Career Development Program of the Ovarian SPORE are to identify and mentor new and developing investigators in ovarian cancer who demonstrate the clear potential to become independent translational researchers as well as attracting established scientists who wish to refocus on ovarian cancer. This will be accomplished through a rigorous review process aimed at identifying the most talented and promising candidate followed by intense effective mentoring, integration into ongoing SPORE activities and close oversight of the individual's progress. In addition to a primary mentor, awardees will have complementary mentors in clinical, basic or population sciences necessary to ensure development of a translational research career. This capitalizes on numerous strengths present within the Mayo environment. The Career Development Program will maintain close oversight over the mentoring activities and progress of the awardee. In turn, the Program will report to the Executive Committee of the Mayo Clinic Ovarian Cancer SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA136393-01A1
Application #
7727456
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2009-07-01
Project End
2014-06-30
Budget Start
2009-07-01
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$68,811
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wu, Chenming; Luo, Kuntian; Zhao, Fei et al. (2018) USP20 positively regulates tumorigenesis and chemoresistance through ?-catenin stabilization. Cell Death Differ 25:1855-1869
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Li, Lei; Liu, Tongzheng; Li, Yunhui et al. (2018) The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization. Oncogene 37:2422-2431
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Wahner Hendrickson, Andrea E; Menefee, Michael E; Hartmann, Lynn C et al. (2018) A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. Clin Cancer Res 24:744-752
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Knijnenburg, Theo A; Wang, Linghua; Zimmermann, Michael T et al. (2018) Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23:239-254.e6
Jung, DeokBeom; Khurana, Ashwani; Roy, Debarshi et al. (2018) Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer. Sci Rep 8:2487

Showing the most recent 10 out of 294 publications